Login
$BTSG
$72.72 +$1.35 (1.89%) After hours

Company Executives

Officer Age In this role Joined 2025 pay Source
Jennifer Phipps
Executive Vice President and Chief Financial Officer, Corporate Secretary
45 Not stated 2017 $4,444,051
Scott Greenwell
Executive Vice President and President, PharMerica
49 Since 2025
1 year
Not stated $1,436,755
Jon Rousseau Also a director
See Remarks
Title from the Form 4 dated Oct 25, 2026
52 Not stated Not stated $17,841,460
Lisa Nalley
See Remarks
Title from the Form 4 dated Jun 5, 2026
53 Not stated Not stated $2,396,266
Jeffrey A. Hopper
See Remarks
Title from the Form 3 dated Oct 26, 2026
Not stated Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 10, 2026 · updated by the 8-K of Jun 12, 2026

Directors
8
serving now
Independent
6 of 6
stated in the proxy; 2 not stated
Average tenure
4.7 years
from year joined
CEO also chairs the board
Yes
Jon Rousseau
Director Age On board Independent Committees Other public boards Pay Source
Jon Rousseau
52 Not stated Not stated None stated None stated Paid as CEO
Olivia Kirtley
75 2024
2 years
Independent None stated None stated Not stated
Max Lin
45 2017
9 years
Independent None stated Cotiviti, Ensora Health, Global Medical Response, Henry Schein, PetVet Care Centers Not stated
Steve Miller
68 2024
2 years
Independent None stated None stated Not stated
Hunter Craig
44 2020
6 years
Independent
Quality and Compliance Committee
123Dentist, Cotiviti, DentalXChange, Heartland Dental, Henry Schein Not stated
Johnny Kim
35 2019
7 years
Independent None stated Argenta, Brightline, Clarify Health Solutions, Global Medical Response, SkinSpirit, SunFire, Therapy Brands Not stated
Tim Wicks
60 2024
2 years
Independent None stated MiniMed Group, Inc. Not stated
Nigam H. Shah Joined Jun 11, 2026
- - -
Quality and Compliance Committee
- -

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

KKR Stockholder
KKR Stockholder, party to the Amended and Restated Stockholders’ Agreement
Amount not stated

Amended and Restated Stockholders’ Agreement granting the KKR Stockholder board nomination rights

With the Company Open in proxy
KKR Stockholder
KKR Stockholder, party to the registration rights agreement
Amount not stated

Registration rights agreement providing demand and piggyback registration rights and expense reimbursement

With the Company Open in proxy
Walgreens Boots Alliance, Inc.
affiliate of the Walgreens Stockholder
Approximately $147.8 million
2025

PharMerica purchases of pharmaceutical products under the Pharmaceutical Purchase and Distribution Agreement

With AmerisourceBergen Drug Corporation (ABDC) Open in proxy
Walgreens Boots Alliance Development GmbH
affiliate of the Walgreens Stockholder
Approximately $13.1 million
2025

PharMerica purchases of generic pharmaceutical products under the WBAD – Membership Agreement

With PharMerica Open in proxy
certain of our senior executive officers and other employees
senior executive officers and other employees holding equity
Amount not stated

Management Stockholders’ Agreement restricting transfers of shares and equity awards held by management stockholders

With the Company and the KKR Stockholder Open in proxy
KKR Stockholder
KKR Stockholder, selling stockholder in the June 2025 Offering
Amount not stated
June 2025

Sale of 13,288,101 shares of common stock by the KKR Stockholder in the June 2025 underwritten offering

With BofA Securities, Inc. and Goldman Sachs & Co. LLC Open in proxy
KKR Stockholder
KKR Stockholder, selling stockholder in the October 2025 Offering
Amount not stated
October 2025

Sale of 14,745,000 shares of common stock by the KKR Stockholder in the October 2025 offering

With BofA Securities, Inc. Open in proxy
KKR Stockholder
KKR Stockholder, selling stockholder in the March 2026 Offering
Amount not stated
March 2026

Sale of 19,715,000 shares of common stock by the KKR Stockholder in the March 2026 offering

With Goldman Sachs & Co. LLC Open in proxy
KKR Stockholder
KKR Stockholder, reimbursed for legal fees in the KKR Offerings
$0.6 million

Company reimbursement of the KKR Stockholder’s legal fees in connection with the KKR Offerings

With the Company Open in proxy
directors and executive officers
directors and executive officers of the Company
Amount not stated

Indemnification agreements requiring the Company to indemnify directors and executive officers to the fullest extent permitted under Delaware law

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support